Susquehanna Fundamental Investments LLC Invests $699,000 in Artivion, Inc. (NYSE:AORT)

Susquehanna Fundamental Investments LLC bought a new position in shares of Artivion, Inc. (NYSE:AORT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 24,448 shares of the company's stock, valued at approximately $699,000. Susquehanna Fundamental Investments LLC owned about 0.06% of Artivion as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Wasatch Advisors LP grew its stake in shares of Artivion by 27.7% in the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock worth $29,791,000 after purchasing an additional 226,160 shares during the last quarter. Next Century Growth Investors LLC raised its stake in shares of Artivion by 29.7% during the fourth quarter. Next Century Growth Investors LLC now owns 492,653 shares of the company's stock valued at $14,085,000 after acquiring an additional 112,918 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Artivion by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company's stock valued at $10,241,000 after buying an additional 8,343 shares in the last quarter. Oberweis Asset Management Inc. boosted its position in Artivion by 10.8% during the fourth quarter. Oberweis Asset Management Inc. now owns 312,900 shares of the company's stock worth $8,946,000 after purchasing an additional 30,500 shares in the last quarter. Finally, Lord Abbett & CO. LLC raised its position in shares of Artivion by 40.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 306,702 shares of the company's stock valued at $8,769,000 after buying an additional 88,902 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Trading Up 1.5 %

AORT traded up $0.42 during mid-day trading on Thursday, reaching $28.80. The stock had a trading volume of 112,103 shares, compared to its average volume of 313,877. The stock has a market capitalization of $1.23 billion, a P/E ratio of -1,440.00 and a beta of 1.54. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $32.33. The firm's fifty day simple moving average is $24.02 and its two-hundred day simple moving average is $27.19.

Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The business had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. On average, equities analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a report on Tuesday. Needham & Company LLC reiterated a "buy" rating and set a $32.00 price objective on shares of Artivion in a research report on Tuesday. JMP Securities reissued a "market outperform" rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday. Finally, Stifel Nicolaus lowered their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $31.40.

Insiders Place Their Bets

In other news, CFO Lance A. Berry sold 3,259 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $89,003.29. Following the sale, the chief financial officer now directly owns 75,805 shares in the company, valued at $2,070,234.55. This represents a 4.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James P. Mackin sold 42,156 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the sale, the chief executive officer now directly owns 663,882 shares in the company, valued at approximately $18,130,617.42. This trade represents a 5.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,799 shares of company stock valued at $2,356,223 over the last ninety days. 7.60% of the stock is owned by insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.